JP2014521660A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521660A5
JP2014521660A5 JP2014523096A JP2014523096A JP2014521660A5 JP 2014521660 A5 JP2014521660 A5 JP 2014521660A5 JP 2014523096 A JP2014523096 A JP 2014523096A JP 2014523096 A JP2014523096 A JP 2014523096A JP 2014521660 A5 JP2014521660 A5 JP 2014521660A5
Authority
JP
Japan
Prior art keywords
peg
acid
glyceryl
pharmaceutical composition
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521660A (ja
JP6479470B2 (ja
Filing date
Publication date
Priority claimed from US13/193,571 external-priority patent/US8951996B2/en
Application filed filed Critical
Publication of JP2014521660A publication Critical patent/JP2014521660A/ja
Publication of JP2014521660A5 publication Critical patent/JP2014521660A5/ja
Application granted granted Critical
Publication of JP6479470B2 publication Critical patent/JP6479470B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523096A 2011-07-28 2012-07-27 17−ヒドロキシプロゲステロンエステル含有経口組成物および関連方法 Active JP6479470B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/193,571 US8951996B2 (en) 2011-07-28 2011-07-28 17-hydroxyprogesterone ester-containing oral compositions and related methods
US13/193,571 2011-07-28
PCT/US2012/048708 WO2013016697A2 (en) 2011-07-28 2012-07-27 17-hydroxyprogesterone ester-containing oral compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017098138A Division JP2017193554A (ja) 2011-07-28 2017-05-17 17−ヒドロキシプロゲステロンエステル含有経口組成物および関連方法

Publications (3)

Publication Number Publication Date
JP2014521660A JP2014521660A (ja) 2014-08-28
JP2014521660A5 true JP2014521660A5 (enExample) 2015-09-03
JP6479470B2 JP6479470B2 (ja) 2019-03-06

Family

ID=47597718

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014523096A Active JP6479470B2 (ja) 2011-07-28 2012-07-27 17−ヒドロキシプロゲステロンエステル含有経口組成物および関連方法
JP2017098138A Pending JP2017193554A (ja) 2011-07-28 2017-05-17 17−ヒドロキシプロゲステロンエステル含有経口組成物および関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017098138A Pending JP2017193554A (ja) 2011-07-28 2017-05-17 17−ヒドロキシプロゲステロンエステル含有経口組成物および関連方法

Country Status (13)

Country Link
US (10) US8951996B2 (enExample)
EP (2) EP3763360A1 (enExample)
JP (2) JP6479470B2 (enExample)
KR (1) KR101957264B1 (enExample)
CN (2) CN103826640A (enExample)
AU (1) AU2012286620B2 (enExample)
BR (1) BR112014001942B1 (enExample)
CA (1) CA2879401C (enExample)
IL (1) IL230665B (enExample)
MX (1) MX385798B (enExample)
RU (1) RU2640912C2 (enExample)
WO (1) WO2013016697A2 (enExample)
ZA (1) ZA201401464B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
KR101561406B1 (ko) * 2015-02-02 2015-10-16 환인제약 주식회사 두타스테라이드 함유 고체 분산체 및 이를 포함하는 조성물
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
MX2017016823A (es) * 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017053416A1 (en) * 2015-09-21 2017-03-30 Prairie Pharmaceuticals LLC Treating auto-immune and auto-inflammatory diseases
MY197560A (en) * 2015-09-21 2023-06-23 Shenzhen Evergreen Therapeutics Co Ltd Pulmonary delivery of progestogen
WO2017059070A1 (en) * 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
WO2017081725A1 (ja) * 2015-11-09 2017-05-18 花王株式会社 口腔用組成物
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR102354954B1 (ko) 2016-04-04 2022-01-24 오메자 엘엘씨 어유 국소 조성물
US10828412B2 (en) 2016-05-06 2020-11-10 Gambro Lundia Ab Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation including mixing and heating therefore
WO2017200987A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US20200179402A1 (en) * 2016-08-03 2020-06-11 Indiana University Research And Technology Corporation Monohydroxylated 17alpha-hydroxyprogesterone caproate for reducing contractility
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
WO2018060866A1 (en) * 2016-09-28 2018-04-05 Dr. Reddy’S Laboratories Limited Oral retinoid compositions
EP4585211A3 (en) 2017-04-14 2025-10-22 Capsugel Belgium NV Pullulan capsules
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ, インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
KR102771577B1 (ko) * 2017-11-27 2025-02-20 유메크린 코그니션 에이비 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형
CA3090203A1 (en) * 2018-02-09 2019-08-15 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
EP4007590A4 (en) * 2019-08-06 2023-08-30 Kirkland, Justin Formulations including dihydrohonokiol
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113616660A (zh) * 2020-05-07 2021-11-09 深圳埃格林医药有限公司 孕激素制剂及其用途
CN111975205B (zh) * 2020-09-04 2022-04-22 内蒙古工业大学 重度磨损截齿修补方法
US12502396B2 (en) 2020-10-27 2025-12-23 Lipocine Inc. Hydroxyprogesterone caproate compositions and methods of use in preventing preterm birth
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
CN116077416B (zh) * 2021-11-05 2024-12-06 深圳埃格林医药有限公司 一种包含孕激素的口服制剂及制备方法和应用
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
JPS57500432A (enExample) * 1980-03-20 1982-03-11
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
US5314882A (en) * 1984-01-03 1994-05-24 International Foundation For Biochemical Endocrinology Method for promoting growth and improved meat quality in meat producing animals with female steroidal hormones
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
GB8730011D0 (en) 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
GB8802671D0 (en) 1988-02-05 1988-03-02 Goodfellow J W Orthopaedic joint components tools & methods
AU5157590A (en) 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
IT1252867B (it) 1991-12-31 1995-06-28 Gentili Ist Spa Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
ATE282423T1 (de) 1994-08-23 2004-12-15 Stoess & Co Gelatine Verwendung von geschmacksneutralem, hydrolysiertem kollagen und mittel enthaltend dasselbe
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
ATE210198T1 (de) 1997-04-28 2001-12-15 Tiberiu Kaszas Verfahren und vorrichtung zur rückgewinnung von rohstoffen aus abfällen und reststoffen
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
PL368744A1 (en) * 2001-11-30 2005-04-04 Solvay Pharmaceuticals Gmbh Prevention of miscarriage with immunomodulating non-endogenous gestagen compounds
US20050123604A1 (en) * 2002-03-07 2005-06-09 Karnachi Anees A. Pharmaceutical compositions
WO2003077923A1 (en) 2002-03-14 2003-09-25 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
US20060127484A1 (en) * 2002-07-05 2006-06-15 Speirs Christopher J Controlled release composition
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CN1231210C (zh) 2002-08-20 2005-12-14 杭州容立医药科技有限公司 黄体酮胶囊组合物及其制备方法
PT1539184E (pt) 2002-08-28 2007-02-28 Robert Casper Regímen de substituição de estrogénio
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
JP2004155780A (ja) 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 生活習慣病改善剤組成物
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
HUE026034T2 (en) 2002-12-13 2016-05-30 Durect Corp Oral delivery system containing an oral high-viscosity carrier
CN1282459C (zh) 2002-12-24 2006-11-01 上海医药工业研究院 黄体酮胶丸及制备方法
ATE553378T1 (de) 2003-02-06 2012-04-15 Hologic Inc Screening und behandlungsverfahren zur vorbeugung von frühgeburten
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
CN1299686C (zh) 2003-04-03 2007-02-14 上海医药工业研究院 黄体酮半固体骨架制剂的组合物
PT1663216E (pt) * 2003-08-29 2012-02-14 Veloxis Pharmaceuticals As Dispersões sólidas que compreendem tacrolímus
CN1623550A (zh) 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
CA2548281C (en) 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2005092441A2 (en) 2004-03-19 2005-10-06 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
US20080275076A1 (en) 2005-03-08 2008-11-06 Per Holm Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
RU2623206C2 (ru) 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
AU2006249349B2 (en) 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
WO2007010559A2 (en) * 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
EP2200588B1 (en) 2007-09-25 2019-03-20 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
WO2009070794A1 (en) 2007-11-29 2009-06-04 Jackson Gregg A Progesterone-containing compositions and devices
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
CA2779270A1 (en) 2009-10-29 2011-05-05 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2544707B1 (en) 2010-03-09 2018-11-21 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Similar Documents

Publication Publication Date Title
JP2014521660A5 (enExample)
RU2014102285A (ru) Пероральные композиции, содержащие сложный эфир 17-гидроксипрогестерона, и соответствующие способы
ES2667944T3 (es) Gránulos y comprimidos orodispersables que contienen oxicodona
US20100086592A1 (en) Modified dosage forms of tacrolimus
RU2011145433A (ru) Перорально распадающиеся таблеточные композиции, содержащие комбинации неопиоидных и опиоидных анальгетиков
CA2812372C (en) Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
JP2012526047A5 (enExample)
CA2829015C (en) Formulation comprising phenylaminopyrimidine derivative as active agent
JP2016514706A5 (enExample)
RU2015128028A (ru) Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки
US12502396B2 (en) Hydroxyprogesterone caproate compositions and methods of use in preventing preterm birth
WO2020115774A1 (en) High drug load extended release formulations
WO2011100668A1 (en) Methods and compositions of civamide to treat diseases of the intestines
JP2008150298A (ja) 溶解性を改善したジフェンヒドラミン含有医薬組成物